P-463 Anti-Müllerian hormone levels in breast cancer patients receiving chemotherapy with or without concurrent luteinizing hormone-releasing hormone agonist: results from the PROMISE phase III trial | Zendy

Camilla Marrocco | Zendy; B Conte | Zendy; Giovanni A. Rossi | Zendy; Chiara Pirrone | Zendy; Diletta Favero | Zendy; C Massarotti | Zendy; Paola Anserini | Zendy; Piero Fregatti | Zendy; Bárbara Cardinali | Zendy; G Buzzati | Zendy; Alessia Levaggi | Zendy; Francesca Poggio | Zendy; Eva Blondeaux | Zendy; Lucia Del Mastro | Zendy; Matteo Lambertini | Zendy

Open Access

P-463 Anti-Müllerian hormone levels in breast cancer patients receiving chemotherapy with or without concurrent luteinizing hormone-releasing hormone agonist: results from the PROMISE phase III trial

Author(s) -

Camilla Marrocco,

B Conte,

Giovanni A. Rossi,

Chiara Pirrone,

Diletta Favero,

C Massarotti,

Paola Anserini,

Piero Fregatti,

Bárbara Cardinali,

G Buzzati,

Alessia Levaggi,

Francesca Poggio,

Eva Blondeaux,

Lucia Del Mastro,

Matteo Lambertini

Publication year - 2022

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/deac107.435

Subject(s) - medicine , anti müllerian hormone , triptorelin , breast cancer , oncology , ovarian reserve , chemotherapy , luteinizing hormone , menopause , premature ovarian failure , gynecology , cancer , hormone , gonadotropin releasing hormone , infertility , pregnancy , biology , genetics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research